anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine. Group of inventions includes a computer-implemented method of operating a system for treating diabetes, a system for treating diabetes and an insulin pump control device. System comprises an insulin pump configured to selectively deliver insulin into the patient's body and a pump control device comprising a communication component. Communication component is configured to perform two-way communication between the insulin pump and the pump control device. Input component is configured to receive a request for an insulin pump to perform an operation that depends on the presence of the insulin pump in the preset state. Processor is configured to request an insulin pump on its current state by means of a communication component to receive information from an insulin pump on its current state, with the possibility of determining whether the current state of the insulin pump matches its preset state. Also, it is possible to send an insulin pump by means of a communication component of the command to perform the specified operation when determining the match of the current state of the insulin pump with its preset state. Insulin pump comprises a switch which controls its operating state. In determining the mismatch of the current state of the insulin pump with its predetermined condition, the processor of the pump control device provides, via the communication component, an additional instruction sending the insulin pump to actuate said switch to change the current state of the insulin pump to the predetermined one.EFFECT: group of inventions makes it possible to automatically and efficiently operate the system for treating diabetes by determining mismatch of the current state of the insulin pump with its preset state, presence of a switch in the insulin pump, which controls its operating state.14 cl, 6 dwg
Rx Only

RIDAURA® (auranofin) contains gold and, like other gold-containing drugs, can cause gold toxicity, signs of which include: fall in hemoglobin, leukopenia below 4,000 WBC/cu mm, granulocytes below 1,500/cu mm, decrease in platelets below 150,000/cu mm, proteinuria, hematuria, pruritus, rash, stomatitis or persistent diarrhea. Therefore, the results of recommended laboratory work (See PRECAUTIONS) should be reviewed before writing each RIDAURA prescription. Like other gold preparations, RIDAURA is only indicated for use in selected patients with active rheumatoid arthritis. Physicians planning to use RIDAURA should be experienced with chrysotherapy and should thoroughly familiarize themselves with the toxicity and benefits of RIDAURA.

In addition, the following precautions should be routinely employed:

  1. The possibility of adverse reactions should be explained to patients before starting therapy.
  2. Patients should be advised to report promptly any symptoms suggesting toxicity. (See PRECAUTIONS—Information for Patients.)
A trial for 6 months will be carried out in 11 Ministry of Health primary care facilities starting in October 2023. This arm consists of the patients whose health markers will be monitored through the study.
Patients received preoperative neoadjuvant therapy: SBRT 12Gy on the first day, and Toripalimab (IV 240mg, q3W) combined with platinum-containing dual drugs on the second day. Two cycles in total.
A computer-implemented process renders, at an EMR (electronic medical record) device positioned at a healthcare provider location, an EMR user interface to access EMR data of a patient. Furthermore, the computer-implemented process receives, via a language interpretation request indicum of the EMR user interface, a request for language interpretation. The computer-implemented process sends, from the EMR device to an EMR server, the EMR data of the patient. Additionally, the computer implemented process receivers, from the EMR server at the EMR device, a visual code indicium (e.g. a QR code). Finally, the computer-implemented process renders, at the EMR device, the visual code indicium to link the EMR device with a language interpretation device also positioned at the healthcare provider location such that the language interpretation device renders a language interpretation session between a healthcare provider and the patient without being rendered by the EMR device.
Procedure for the obtaining of hydrosoluble salts from the trimetoprima (5- (3,4,5-trimetoxibencil) -2,4-diaminopirimidina) corresponding to the formula: ** formula **. X- where x is a carboxylic acid containing one or more hydroxylic functions. Represents the trimetoprimate in aqueous medium with a polyhydroxyled organic acid that may be the fluconic acid, the lactobionic acid or the pantothenic acid. The solution that is obtained is filtered to eliminate some insoluble residual impurities. The filtered solution is concentrated to the vacuum and is liofilized or atomized for its conservation in the form of dust. This product is used as an antimicrobial agent. (Machine-translation by Google Translate, not legally binding)
The purpose of this study is to test the practicality of mothers and children utilizing the WECS Relational Health Toolkit. The Cuddle and Calm Book, Well Baby Book, mother and child mutual narrative activity card, Bottle of Feelings, Mother's Socioemotional Support Circle, and the WECS for emotional connection make up the preschool WECS Relational Health toolkit. The WECS Relational Health Toolkit provides family-based resources to help mothers and children emotionally connect. The WECS Relational Health Toolkit is designed to create emotional connection and establish mother-child autonomic co-regulation, which helps shape autonomic state and behavior of the mother and child and therefore determines early child development and mother well-being. The investigators will test whether this toolkit can be a positive part of a standard preschool education program. Practicality will be measured through virtual participant attendance, a participant survey, and staff notes. Effects of this program on the emotional connection of mother-child pair will be measured through the Welch Emotional Connection Screen (WECS). Effects on child behaviors will be measured through the WECS-Parent Report (WECS-PR), SDQ, and Survey of Wellbeing of Young Children Baby Pediatric Symptom Checklist (BPSC) or the Preschool Pediatric Symptom Checklist (PPSC) subscales (age-dependent). We will also measure symptoms of depression in the mothers using the Center for Epidemiological Studies-Depression (CES-D) before and after the introduction to the Toolkit. We will also assess differences in developmental progress using the Milestones subscale of the SWYC.
Participants will be administered bevacizumab 15 milligram per kilogram (mg/kg) via a 30 minute (min) intravenous (IV) infusion on Day 1 of each 21-day cycle. Niraparib will be administered orally once a day continuously throughout each 21-day cycle (84-day cycle after amendment 2). On Day 1 of each cycle, niraparib will be administered upon completion of bevacizumab infusion. The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count.
Obese patients will be recruited from the outpatient Clinic of Obesity at the INCMNSZ. They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
The invention discloses a heptapeptide PGKPLFL and an application thereof. The amino acid sequence of the synthetic polypeptide is shown as follows: Pro-Gly-Lys-Pro-Leu-Phe-Leu abbreviated to PGKPLFL, the molecular weight is 771.6, and the purity is 98.4%. The polypeptide is synthesized by a polypeptide synthesizer with a solid-phase synthesis method. Through in-vitro antitumor activity detection, the polypeptide has a certain inhibition effect on hepatoma cells HepG-2 and breast cancer cells MCF-7 in the range of 100-500 mu g/mL. The polypeptide has in-vitro proliferation inhibition rates of 53.72% and 50.25% for the HepG-2 and the MCF-7 respectively at 500 mu g/mL. The synthetic polypeptide has in-vitro antitumor activity and can be applied to the field of biological pharmacy.
Recently, laryngeal mask airway (LMA) placements are frequently performed for general anesthesia. The investigators occasionally encounter a clinical situation to perform internal jugular vein (IJV) cannulation after LMA insertion, especially for difficult airway in subjects undergoing major surgery. However, anatomic relations of IJV and common carotid artery (CCA) in patient with LMA placement have been reported to be different from those in patients with endotracheal tube. The degree of overlapping of the right IJV and CCA after LMA placement was greater than before LMA placement. Furthermore, there are many cases of complete overlapping right IJV and CCA after LMA placement. Therefore, the risk of puncturing CCA increases when the investigators try to cannulate IJV after LMA placement. Furthermore, the central landmark commonly used for IJV cannulation was proved to show low success rate after LMA placement in previous report. Previous study recommended the lower puncture point near that area where the clavicular head of the sternocleidomastoid muscle attaches to the clavicle, because CCA was not observed in the vicinity of the IJV after LMA insertion. Even though they performed test puncture at the lower puncture point in 20 patients and found no complications, the lower puncture point is not the usual site for IJV cannulation for most anesthesiologists. It is known that increased head rotation is associated with high probability of CCA contact. The investigators carefully examined the anatomic relations of IJV and CCA after LMA insertion with ultrasonography, and found that the degree of overlapping is different according to the degree of head rotation. The investigators postulated that if the degree of overlapping is different according to the degree of head rotation after LMA insertion, the investigators can find the angle of head rotation for least overlapping and reduce the risk of CCA puncture. Therefore, the investigators tried (1) to find the optimal head rotation angle appropriate for puncturing IJV after LMA placement, and (2) to find suitable landmark adequate for IJV cannulation after LMA placement.
A repeater providing data exchange with a medical device for remote patient care and method thereof are provided. A plurality of interfaces include a medical device interface interconnected with a medical device, a wireless interface coupled to a wireless medium, and a wired interface coupled to a wired medium. An interface selector includes a test module operable over the wireless interface and the wired interface to evaluate conditions on each respective medium that could affect data exchange over each of the interfaces. The interface selector further includes a selection module specifying data exchange to occur using one of the wireless interface and the wired interface based on the evaluated conditions. An interrogator module exchanges data with the medical device over the medical device interface. A data transfer module exchanges the data with an external device over the specified interface.
The group of patients with Passive Range Of Motion (P-ROM), i.e. without active movements of the hand at the baseline, is subjected to two session per day in the morning and in the afternoon over a period of two weeks (5 days per week). Each session is composed by 30 min of continuous passive motion rehabilitation and 60 min of physical and occupational therapy.
Patients will receive PVI guided fluids during surgery PVI to be maintained below 12% if PVI \>12 then colloid bolus 200ml will be given. Lung Ultrasonography will be performed post-intubation as baseline and at the end of surgery before extubation in 4 Lung zones in both lungs to measure total number of B-lines.
The group will realize 2 classes per week, lasting one our, of Pilates under supervision of a trained instructor. The training program will last 3 months.
A gamboge detoxification processing technology and a gamboge processing method relate to the field of traditional Chinese medicine. And heating the obtained first filtrate and zeolite together to boil, and filtering to obtain a second filtrate. Part of toxic substances in the gamboge are decomposed and destroyed in the boiling process and volatilize along with water vapor, and part of substances which are difficult to volatilize can be adsorbed by the porous structure of the zeolite, so that the dual toxicity reducing effect is achieved. And concentrating the second filtrate to remove excessive water to obtain gamboge slurry, and steaming the gamboge slurry at high temperature and high pressure to decompose and destroy toxic substances in gamboge and kill bacteria in gamboge to a certain extent. The processing method has simple operation and low requirement for equipment, and can remove toxic components in resina Garciniae completely by multiple attenuation processes. The processed gamboge obtained by the process has low toxicity, high content of effective components and higher medicinal value.
The present invention relates to a novel Lactobacillus fermentum EFEL6800 fermentation starter with probiotics activity. The Lactobacillus fermentum EFEL6800 (KACC 81106BP), discovered in the present invention, showed suitability as a fermentation starter and excellent probiotics properties. The strain of the present invention can grow even at low temperature (15℃) and produce an appropriate amount of acid and abundant aroma components and metabolites, and thus is determined to be suitable as a fermentation starter. In addition, the strain has resistance against bile acid and probiotics properties with high antioxidant activity. In addition, the strain of the present invention does not contain a biogenic amine gene and is not haemolytic, thereby being safe for use in food fermentation. In conclusion, the Lactobacillus fermentum EFEL6800 is suitably used as a fermentation strain for vegetables, fruits, grains, and the like and can be used as a healthy functional probiotics starter with anti-inflammatory activity.
A method is disclosed for treating cancerous or benign conditions of an organ by selective irradiation of the organ tissue with focused energy. The method includes the steps of inserting an E-field probe sensor to an appropriate depth in the organ tissue, monitoring temperatures of the skin surface adjacent the organ (if focused energy is used), positioning two or more energy applicators around the organ, setting the initial power level delivered to each energy applicator, setting the initial relative phase delivered to each energy applicator to focus the energy at the E-field probe positioned in the organ tissue(if focused energy is used), delivering energy to the two or more energy applicators to selectively irradiate the organ tissue with focused energy and treat at least one of cancerous and benign conditions of the organ, adjusting the level of power to be delivered to each energy applicator during treatment based on the monitored skin temperatures, monitoring the energy delivered to the energy applicators, determining total energy delivered to the energy applicators and displaying the total energy in real time during the treatment, and completing the treatment when the desired total energy dose has been delivered by the energy applicators to the organ. Either focused or non-focused energy may be employed with microwave energy applicators being the preferred energy source. However, any combination of energy applicators such as electromagnetic, ultrasound, radio frequency and laser may be used together to form the focused energy. Non-focused energy may be combined with focused energy to enhance the thermotherapy. Several applications for breast cancer treatment include treatment of advanced and early stage breast cancer, breast cancer prevention, and treatment of benign breast disease and ductal carcinoma in situ.
The invention provides a computer system and method for managing a user's health. The invention provides a user with a health plan comprising executable actionable tasks. The health plan is selected for the user according to predefined criteria. Users are given incentives for execution of the tasks of the health plan. The software of the invention receives medical data pertaining to a user, analyzes the medical data and displays the analysis of the medical data in a highly visual display. In one embodiment, medical data is displayed on a color-coded gauge indicating desirability of the medical data, and brief textual messages are provided in layman's terms to indicate any necessary follow-up. The invention may be provided as a website, or as a software application for use on a user's personal electronic device.
BACKGROUND: Secondary lymphoedema (SL) is one of the most common and, at the same time, most significant consequences and complications of modern oncological therapy. Although a thorough patient history and physical examination are sufficient to substantiate a suspicion, it is essential to perform functional imaging of the lymphatic system for a targeted diagnosis and determination of severity. For this purpose, techniques such as MR and ICG lymphography as well as ultra-high-frequency ultrasound examinations have been developed and validated in recent years. The selective use of these techniques has allowed for individualized indications and successful stage-dependent treatment using (super)microsurgical techniques to restore regional lymphatic drainage in the context of intensified conservative therapy.
METHOD: Systematic review of the literature on the diagnosis and treatment of SL with subsequent analysis and classification of the results into evidence levels according to the Oxford Centre for Evidence-Based Medicine and the GRADE Scale.
RESULTS: The established and validated diagnosis of SL includes imaging (ICG fluorescence lymphography, MR lymphography and Tc-99 functional lymphoscintigraphy) in case of a clinical suspicion and in high-risk patients. Complex physical decongestion therapy (CPE) is superior to physical therapy or compression alone. (Super)microsurgery of SL allows for a postoperative reduction in the frequency of CPE, a reduction of erysipelas rates, a volume reduction of the lymphomatous extremity and, if carried out prophylactically, a lower incidence of SL. Suction-assited lipectomy can produce long-term, stable reductions in circumference and an improvement in quality of life.
CONCLUSION: Patients with SL benefit from conservative therapy with regular re-evaluation. Patients with a high risk for SL or with clinical deterioration or persistent symptoms under guideline-based conservative therapy can benefit from (super)microsurgical therapy after an individualized functional diagnostic evaluation of the lymphatic system. Excisional dermolipectomies or lympholiposuctions are available and effective for advanced and refractory stages.
There is a growing appreciation of the wide range of sleep-wake disturbances that occur frequently in Parkinson's disease. These are known to be associated with a range of motor and non-motor symptoms and significantly impact not only on the quality of life of the patient, but also on their bed partner. The underlying causes for fragmented sleep and daytime somnolence are no doubt multifactorial but there is clear evidence for circadian disruption in Parkinson's disease. This appears to be occurring not only as a result of the neuropathological changes that occur across a distributed neural network, but even down to the cellular level. Such observations indicate that circadian changes may in fact be a driver of neurodegeneration, as well as a cause for some of the sleep-wake symptoms observed in Parkinson's disease. Thus, efforts are now required to evaluate approaches including the prescription of precision medicine to modulate photoreceptor activation ratios that reflect daylight inputs to the circadian pacemaker, the use of small molecules to target clock genes, the manipulation of orexin pathways that could help restore the circadian system, to offer novel symptomatic and novel disease modifying strategies.
BACKGROUND: One-fourth of men older than 70 years have lower urinary tract symptoms (LUTS) that impair their quality of life. Transurethral resection of the prostate (TURP) is considered the gold standard for surgical treatment of LUTS caused by benign prostatic hyperplasia (BPH) that cannot be managed conservatively or pharmacologically. However, TURP is only an option for patients fit for surgery and can result in complications. Transurethral microwave thermotherapy (TUMT) and prostatic artery embolisation (PAE) are alternative minimally invasive surgical therapies (MISTs) performed in an outpatient setting. Both treatments have shown to reduce LUTS with a similar post-procedure outcome in mean International Prostate Symptom Score (IPSS). It is however still unknown if TUMT and PAE perform equally well as they have never been directly compared in a randomised clinical trial. The objective of this clinical trial is to assess if PAE is non-inferior to TUMT in reducing LUTS secondary to BPH.
METHODS: This study is designed as a multicentre, non-inferiority, open-label randomised clinical trial. Patients will be randomised with a 1:1 allocation ratio between treatments. The primary outcome is the IPSS of the two arms after 6 months. The primary outcome will be evaluated using a 95% confidence interval against the predefined non-inferiority margin of + 3 points in IPSS. Secondary objectives include the comparison of patient-reported and functional outcomes at short- and long-term follow-up. We will follow the patients for 5 years to track long-term effect. Assuming a difference in mean IPSS after treatment of 1 point with an SD of 5 and a non-inferiority margin set at the threshold for a clinically non-meaningful difference of + 3 points, the calculated sample size was 100 patients per arm. To compensate for 10% dropout, the study will include 223 patients.
DISCUSSION: In this first randomised clinical trial to compare two MISTs, we expect non-inferiority of PAE to TUMT. The most prominent problems with MIST BPH treatments are the unknown long-term effect and the lack of proper selection of candidates for a specific procedure. With analysis of the secondary outcomes, we aspire to contribute to a better understanding of durability and provide knowledge to guide treatment decisions.
TRIAL REGISTRATION: ClinicalTrials.gov NCT05686525. Registered on January 17, 2023, https://clinicaltrials.gov/study/NCT05686525 .
This was an open label study to determine the efficacy and safety of treatment with ceritinib in patients with a diagnosis of solid tumors or hematological malignancies that had been pre-identified (prior to study consent) to have ALK or ROS1 positive mutations, translocations, rearrangements or amplifications and whose disease had progressed on or after standard treatment. The study consisted of a treatment phase where all patients received ceritinib capsules for a total dose of 750 mg daily for up to 8 cycles of 28 days. Disease assessments for clinical benefit were performed every 8 weeks until disease progression or end of treatment. Following discontinuation of treatment for any reason, patients were followed for safety for 30 days. Survival information was collected every 3 months until 2 years after the last patient had enrolled into the study. Study was amended to allow for discontinuation of survival period if primary endpoint was not met.

Study was terminated due to low enrollment.
Up to 12 weeks of usual physiotherapy care. Three sessions per week. One hour per session.